Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma

Phase 1/2 Terminated 29 enrolled Dynavax Technologies Corporation

SequentialOpen-labelTreatment

Summary

To assess the safety and tolerability of escalating doses of SD-101 in combination with localized low-dose radiation therapy in adult subjects with untreated low-grade B-cell lymphoma.

Timeline

Start: 2014-10
Primary completion: 2017-04
Completion: 2017-04

Outcome

Outcome not reported

Stopped: “The sponsor terminated the trial early because there was sufficient data to make a decision about SD-101 in the lymphoma development program.”

Publications

Mooney KL, Czerwinski DK, Shree T, Frank MJ, Haebe S, Martin BA, Testa S, Levy R, Long SR. Serial FNA allows direct sampling of malignant and infiltrating immune cells in patients with B-cell lymphoma receiving immunotherapy. Cancer Cytopathol. 2022 Mar;130(3):231-237. doi: 10.1002/cncy.22531. Epub 2021 Nov 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SD-101	Oligonucleotide (other)	1 mg/ml	Other
Subject	SD-101	Oligonucleotide (other)	2 mg/ml	Other
Subject	SD-101	Oligonucleotide (other)	4 mg/ml	Other
Subject	SD-101	Oligonucleotide (other)	8 mg/ml	Other